9th Annual Biomarkers Congress

View Profile


Grant Support

Start year End year Title Source Position
1. 2010 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Adjuvant Methotrexate Treatment for Giant Cell Arteritis FDA, Wyeth Ayerst, and the George Storer Foundation. Principal Investigator
2. 2003 2010 Vasculitis Clinical Research Consortium NIH site-PI
3. 2003 2010 Rituximab in ANCA-Associated Vasculitis NIH, Immune Tolerance Network, Genentech Co-PI
4. 2001 2008 Wegener's Granulomatosis Genetic Repository, (WGGER) NIH Co Investigator
5. 1999 2008 Wegener's Granulomatosis Etanercept Trial (WGET) NIH/ FDA PI
6. 2004 2007 Vasculitis Outcome Measures: Development and Validation NIH CO-PI
7. 2002 2004 Short Term Cyclophosphamide followed by alternative therapy in WG Wegener's Granulomatosis Assoc (WGA) Hoffman, Villa Forte Co-PI
8. 2000 2004 Search for Infectious Etiology of Wegener's Disease NIH Co-PI
9. 1995 1998 Clinical application of “edema-weighted� magnetic resonance imaging in Takayasu’s arteritis Cleveland Clinic Foundation Principal Investigator
10. 1994 1998 Surrogate markers of disease activity in patients with systemic vasculitides Cleveland Clinic Foundation, Specialty Laboratories Principal Investigator
11. 1994 1996 The frequency of mediastinal masses and hilar adenopathy in patients with Wegener’s granulomatosis Cleveland Clinic Foundation, NIH/NIAID Principal Investigator
12. 1993 1995 Patient-reported effects of disease on health, function and income in Wegener’s granulomatosis The Edward Lozick and Marvin and Olga Esch Foundations for Vasculitis Research Principal Investigator
13. 1988 1995 Role of environmental exposures in precipitating Wegener’s granulomatosis Cleveland Clinic Foundation, NIH/NIAID Principal Investigator
14. 1994 Analysis of Fcg receptors in Wegener’s granulomatosis NIH Funding through grant to Dr. Kimberly Co-Investigator
15. 1988 1993 Treatment of glucocorticoid-resistant or relapsing Takayasu’s arteritis with methotrexate NIH/NIAID Principal Investigator
16. 1990 1992 The utility of indium-111 mixed leukocyte scans to detect active disease in Takayasu’s arteritis. NIH/NIAID Principal Investigator
17. 1990 1992 The effect of estradiol on leukocyte binding to activate endothelial cells NIH/NIAID Co-Investigator
18. 1990 1992 Study of angiogenic factors from sera of patients with systemic vasculitis NIH/NIAID Co-Investigator
19. 1990 1992 The epidemiology of Wegener’s granulomatosis NIH/NIAID Co-Investigator
20. 1988 1992 Clinical features and management of subglottic stenosis in patients with Wegener’s granulomatosis NIH/NIAID Principal Investigator
21. 1988 1992 Study of the prognostic value of antineutrophil cytoplasmic antibodies in patients with Wegener’s granulomatosis NIH/NIAID Principal Investigator
22. 1988 1992 Long-term study of Takayasu’s arteritis at National Institutes of Health NIH/NIAID Principal Investigator
23. 1988 1992 Prospective study of Wegener’s granulomatosis in children and adolescents NIH/NIAID Principal Investigator
24. 1988 1992 Development of new techniques to treat subglottic stenosis in Wegener’s granulomatosis NIH/NIAID Co-Investigator
25. 1988 1992 Treatment of Wegener’s granulomatosis with glucocorticoids and methotrexate NIH/NIAID Principal Investigator
26. 1988 1992 Establishment of a registry and database for vasculitis at the National Institutes of Health NIH/NIAID Principal Investigator
27. 1988 1992 Cyclophosphamide-induced cystitis in bladder cancer in patients with Wegener’s granulomatosis NIH/NIAID Co-Investigator
28. 1989 1991 Study of the utility of trimethaprim sulfamethoxizole in the treatment of limited forms of Wegener’s granulomatosis NIH/NIAID Principal Investigator
29. 1988 1991 Prospective analysis of Wegener’s granulomatosis at the National Institutes of Health NIH/NIAID Principal Investigator
30. 1989 1990 Study of intractable vasculitis, resorptive osteolysis and immunity to type I collagen in type IV Ehlers Danlos syndrome NIH/NIAID Principal Investigator
31. 1989 1990 Surgical pathology of the lung in Wegener’s granulomatosis NIH/NIAID Principal Investigator
32. 1989 1990 Endothelins: Peptides with potent vasoactive properties are produced by human macrophages NIH/NIAID Co-Investigator
33. 1989 1990 Antineutrophil cytoplasmic antibody production in the respiratory tract of patients with Wegener’s granulomatosis NIH/NIAID Principal Investigator
34. 1988 1990 Interpretation of head and neck biopsies in Wegener’s granulomatosis. Pathologic study of 126 biopsies in 70 patients NIH/NIAID Co-Investigator
35. 1988 1989 Treatment of Wegener’s granulomatosis with intermittent high-dose intravenous cyclophosphamide NIH/NIAID Principal Investigator
36. 1984 1985 Study of oxalate arthropathy in end-stage renal failure in humans Mary Imogene Bassett Hospital Research Institute Principal Investigator
37. 1984 1985 Study of calcium oxalate tissue injury in the rat remnant kidney model for chronic renal failure Mary Imogene Bassett Hospital Research Institute Principal Investigator
38. 1981 Arachnoiditis in dogs: A possible model for human disease Research Institute of the Mary Imogene Bassett Hospital Principal Investigator
39. 1967 1968 Adaptation of colorimetric method to quantify chloroethyl-triazeno-imidazole-carboxamide in blood National Cancer Institute Principal Investigator
40. 1967 1968 Sequential chemotherapy with cyclophosphamide and cytosine arabinoside in mice with advanced leukemia L1210 National Cancer Institute Principal Investigator


4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.